Prestige Consumer Healthcare Inc.PBH
Prestige Consumer Healthcare Inc. Segments Disclosure
Business Segments
Segment information has been prepared in accordance with the Segment Reporting topic of FASB ASC 280. Our reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. The primary measure used by our chief operating decision maker ("CODM") to evaluate the performance of our operating segments and allocate resources to these segments is contribution margin, which we define as gross profit less advertising and marketing expenses. Information regarding total assets by operating segment is not provided to our CODM. Our CODM is our Chief Executive Officer.
The tables below summarize information about our operating and reportable segments.
| Year Ended March 31, 2025 | |||||||||||||||||
| (In thousands) | North American OTC Healthcare | International OTC Healthcare | Consolidated | ||||||||||||||
| Total segment revenues* | $ | 960,010 | $ | 177,752 | $ | 1,137,762 | |||||||||||
| Cost of sales | 428,871 | 74,428 | 503,299 | ||||||||||||||
| Gross profit | 531,139 | 103,324 | 634,463 | ||||||||||||||
| Advertising and marketing | 129,431 | 26,292 | 155,723 | ||||||||||||||
| Contribution margin | $ | 401,708 | $ | 77,032 | 478,740 | ||||||||||||
| Other operating expenses** | 141,965 | ||||||||||||||||
| Operating income | $ | 336,775 | |||||||||||||||
*Intersegment revenues of $3.9 million were eliminated from the North American OTC Healthcare segment.
**Other operating expenses for the year ended March 31, 2025 includes a tradename impairment charge of $12.5 million.
| Year Ended March 31, 2024 | |||||||||||||||||
| (In thousands) | North American OTC Healthcare | International OTC Healthcare | Consolidated | ||||||||||||||
| Total segment revenues* | $ | 958,260 | $ | 167,097 | $ | 1,125,357 | |||||||||||
| Cost of sales | 429,361 | 71,548 | 500,909 | ||||||||||||||
| Gross profit | 528,899 | 95,549 | 624,448 | ||||||||||||||
| Advertising and marketing | 131,494 | 21,821 | 153,315 | ||||||||||||||
| Contribution margin | $ | 397,405 | $ | 73,728 | 471,133 | ||||||||||||
| Other operating expenses | 128,704 | ||||||||||||||||
| Operating income | $ | 342,429 | |||||||||||||||
* Intersegment revenues of $3.7 million were eliminated from the North American OTC Healthcare segment.
| Year Ended March 31, 2023 | |||||||||||||||||
| (In thousands) | North American OTC Healthcare | International OTC Healthcare | Consolidated | ||||||||||||||
| Total segment revenues* | $ | 973,774 | $ | 153,951 | $ | 1,127,725 | |||||||||||
| Cost of sales | 441,844 | 60,587 | 502,431 | ||||||||||||||
| Gross profit | 531,930 | 93,364 | 625,294 | ||||||||||||||
| Advertising and marketing | 123,926 | 21,135 | 145,061 | ||||||||||||||
| Contribution margin | $ | 408,004 | $ | 72,229 | 480,233 | ||||||||||||
| Other operating expenses** | 502,648 | ||||||||||||||||
| Operating loss | $ | (22,415) | |||||||||||||||
*Intersegment revenues of $4.3 million were eliminated from the North American OTC Healthcare segment.
**Other operating expenses for the year ended March 31, 2023 includes a tradename impairment charge of $321.4 million and a goodwill impairment charge of $48.8 million.
The tables below summarize information about our segment revenues from similar product groups.
| Year Ended March 31, 2025 | |||||||||||||||||
| (In thousands) | North American OTC Healthcare | International OTC Healthcare | Consolidated | ||||||||||||||
| Analgesics | $ | 112,173 | $ | 5,524 | $ | 117,697 | |||||||||||
| Cough & Cold | 82,533 | 23,681 | 106,214 | ||||||||||||||
| Women's Health | 216,335 | 20,496 | 236,831 | ||||||||||||||
| Gastrointestinal | 174,891 | 81,052 | 255,943 | ||||||||||||||
| Eye & Ear Care | 158,858 | 24,464 | 183,322 | ||||||||||||||
| Dermatologicals | 120,770 | 8,177 | 128,947 | ||||||||||||||
| Oral Care | 81,868 | 13,162 | 95,030 | ||||||||||||||
| Other OTC | 12,582 | 1,196 | 13,778 | ||||||||||||||
| Total segment revenues | $ | 960,010 | $ | 177,752 | $ | 1,137,762 | |||||||||||
| Year Ended March 31, 2024 | |||||||||||||||||
| (In thousands) | North American OTC Healthcare | International OTC Healthcare | Consolidated | ||||||||||||||
| Analgesics | $ | 111,996 | $ | 5,455 | $ | 117,451 | |||||||||||
| Cough & Cold | 93,575 | 25,445 | 119,020 | ||||||||||||||
| Women's Health | 217,103 | 23,318 | 240,421 | ||||||||||||||
| Gastrointestinal | 160,889 | 70,721 | 231,610 | ||||||||||||||
| Eye & Ear Care | 156,553 | 22,870 | 179,423 | ||||||||||||||
| Dermatologicals | 123,288 | 5,814 | 129,102 | ||||||||||||||
| Oral Care | 83,212 | 13,093 | 96,305 | ||||||||||||||
| Other OTC | 11,644 | 381 | 12,025 | ||||||||||||||
| Total segment revenues | $ | 958,260 | $ | 167,097 | $ | 1,125,357 | |||||||||||
| Year Ended March 31, 2023 | |||||||||||||||||
| (In thousands) | North American OTC Healthcare | International OTC Healthcare | Consolidated | ||||||||||||||
| Analgesics | $ | 116,582 | $ | 2,680 | $ | 119,262 | |||||||||||
| Cough & Cold | 100,218 | 26,770 | 126,988 | ||||||||||||||
| Women's Health | 231,754 | 19,597 | 251,351 | ||||||||||||||
| Gastrointestinal | 156,957 | 69,626 | 226,583 | ||||||||||||||
| Eye & Ear Care | 151,879 | 19,197 | 171,076 | ||||||||||||||
| Dermatologicals | 119,822 | 3,919 | 123,741 | ||||||||||||||
| Oral Care | 85,542 | 12,085 | 97,627 | ||||||||||||||
| Other OTC | 11,020 | 77 | 11,097 | ||||||||||||||
| Total segment revenues | $ | 973,774 | $ | 153,951 | $ | 1,127,725 | |||||||||||
Our total segment revenues by geographic area are as follows:
| Year Ended March 31, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
| United States | $ | 897,540 | $ | 886,470 | $ | 953,222 | |||||||||||
| Rest of world | 240,222 | 238,887 | 174,503 | ||||||||||||||
| Total | $ | 1,137,762 | $ | 1,125,357 | $ | 1,127,725 | |||||||||||
Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:
March 31, 2025 (In thousands) | North American OTC Healthcare | International OTC Healthcare | Consolidated | ||||||||||||||
| Goodwill | $ | 498,936 | $ | 28,489 | $ | 527,425 | |||||||||||
| Intangible assets | |||||||||||||||||
| Indefinite-lived | 2,068,752 | 68,234 | 2,136,986 | ||||||||||||||
| Finite-lived | 141,234 | 17,130 | 158,364 | ||||||||||||||
| Intangible assets, net | 2,209,986 | 85,364 | 2,295,350 | ||||||||||||||
| Total | $ | 2,708,922 | $ | 113,853 | $ | 2,822,775 | |||||||||||
March 31, 2024 (In thousands) | North American OTC Healthcare | International OTC Healthcare | Consolidated | ||||||||||||||
| Goodwill | $ | 498,936 | $ | 28,797 | $ | 527,733 | |||||||||||
| Intangible assets | |||||||||||||||||
| Indefinite-lived | 2,092,853 | 74,309 | 2,167,162 | ||||||||||||||
| Finite-lived | 135,932 | 17,489 | 153,421 | ||||||||||||||
| Intangible assets, net | 2,228,785 | 91,798 | 2,320,583 | ||||||||||||||
| Total | $ | 2,727,721 | $ | 120,595 | $ | 2,848,316 | |||||||||||
Our goodwill and intangible assets by geographic area are as follows:
| Year Ended March 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| United States | $ | 2,708,922 | $ | 2,727,721 | |||||||
| Rest of world | 113,853 | 120,595 | |||||||||
| Total | $ | 2,822,775 | $ | 2,848,316 | |||||||
Free Sentinel
Track for freeWant the next Prestige Consumer Healthcare Inc. segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Prestige Consumer Healthcare Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.